Capital Impact Advisors, LLC Cellectis S.A. Transaction History

Capital Impact Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$8.01 - $12.84 $1.09 Million - $1.75 Million	-136,557 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$11.94 - $16.09 $927,117 - $1.25 Million	-77,648 Reduced 36.25%	136,557 $1.72 Million
Q2 2021 Aug 17, 2021	SELL	$14.36 - $20.93 $1.9 Million - $2.77 Million	-132,325 Reduced 38.19%	214,205 $3.31 Million
Q1 2021 May 18, 2021	BUY	$18.19 - $33.25 $5.02 Million - $9.18 Million	276,230 Added 392.93%	346,530 $7 Million
Q4 2020 Feb 12, 2021	BUY	$15.87 - $31.64 $1.12 Million - $2.22 Million	70,300 New	70,300 $1.9 Million

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.